- BNF:
- Immune system/malignant disease
- Status:
- Red
- Decision Date:
- January 2018
Comments
RED:
- NICE TA495 with aromatase inhibitor for previously untreated hormone receptor positive, HER2- negative, locally advanced or metastatic breast cancer.
- NICE TA619 - with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer. (Decision date - February 2020)
- NICE TA836 - Palbociclib with fulvestrant for treating hormone receptor-positive,
HER2-negative advanced breast cancer after endocrine therapy. (Decision date - November 2022)
NHSE is the responsible commissioner.
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
search again